Photo: FDA Director-General Eric Domingo presents data on adverse events following immunization during a virtual media forum on Thursday. Photo courtesy: screenshot from media forum

FDA Director-General Eric Domingo presents data on adverse events following immunization during a virtual media forum on Thursday, July 8, 2021. (Screenshot from an online media forum)

MANILA, Philippines — While still in talks with international makers of COVID-19 vaccines, the government has started planning to have them packaged locally sometime in 2022, Director General Eric Domingo of the Food and Drug Administration (FDA) said during the pretaped weekly briefing with President Rodrigo Duterte that aired on Monday.

The national task force on vaccine self-sustainability, headed by the Department of Science and Technology, along with the Department of Trade and Industry and the Department of Health, is still in talks with vaccine makers abroad for a possible technology transfer.

“Our plan by next year is to have at least what we call ‘fill and finish’ — meaning, the bulk product will be brought here in the Philippines and then we will repackage that in small vials, ampules, or syringes,” he said.

Meanwhile, the production of other kinds of vaccines is slated to begin in 2023, the FDA chief said.

According to Domingo, the Philippines is talking with vaccine makers in Cuba, China, Russia, and some European countries.

The DTI is handling the partnership negotiations while the DOST is in charge of the development of factories and facilities, he added.

RELATED STORIES

DOST: 2 more firms express interest in local vaccine manufacturing

Glovax to start vaccine ‘form/fill and finish’ operations in 2022

atm

Subscribe to our daily newsletter

Read Next

Don’t miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

For feedback, complaints, or inquiries, contact us.





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here